Cost comparison by treatment arm and center‐level variations in cost and inpatient days on the phase <scp>III</scp> high‐risk B acute lymphoblastic leukemia trial <scp>AALL</scp>0232
Amanda M. DiNofia(Children's Hospital of Philadelphia), Richard Aplenc(Children's Hospital of Philadelphia), Stephen P. Hunger(Children's Hospital of Philadelphia), Viviane C. Cahen(Children's Hospital of Philadelphia), Alix E. Seif(Radiation Oncology Institute), Brian T. Fisher(Children's Hospital of Philadelphia), Naomi Winick(The University of Texas Southwestern Medical Center), Matt Hall(Child Health Corporation of America), William L. Carroll(NYU Langone Health), Meenakshi Devidas(National Institutes of Health), Eric Larsen(University of Massachusetts Chan Medical School), Yuan‐Shung Huang(Children's Hospital of Philadelphia), Yimei Li(Children's Hospital of Philadelphia)
Cited by 14
Related Papers
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
|Clinical Infectious Diseases|2019|2.8k
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
|Journal of Clinical Oncology|2012|1.2k